Added to YB: 2025-04-29
Pitch date: 2025-04-26
ARGX [bullish]
argenx SE
+38.92%
current return
Author Info
FluentInQuality invests in high-quality businesses that generate steady and sustainable cashflows, proven track records, and the potential to act as a true compounding machines over the long run. Sign up for the newsletter.
Company Info
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
Market Cap
EUR 55.4B
Pitch Price
EUR 542.20
Price Target
N/A
Dividend
N/A
EV/EBITDA
72.01
P/E
38.93
EV/Sales
14.00
Sector
Biotechnology
Category
growth
High-Quality European Compounders You Need In Your Portfolio - argenx SE
ARGX: Vyvgart FcRn blocker for autoimmune diseases - €1B+ annualized revenue, expanding from gMG to CIDP and multiple indications. Subcutaneous formulation enhances market reach. Platform approach (not single asset) with antibody tech targeting underserved chronic markets. Global rollout (EU/Japan/China) underway. Margins improving as company scales.
Read full article (2 min)